Plus Therapeutics Presents Positive Phase 1 Data from ReSPECT-GBM Clinical Trial at the European Society for Medical Oncology Congress 2022 (GlobeNewswire) - Sep 12, 2022 - P1/2 | N=55 | ReSPECT (NCT01906385) | Sponsor: Plus Therapeutics | "Plus Therapeutics...announced Phase 1 data from the ReSPECT-GBM Phase 1/2a dose escalation clinical trial...in recurrent glioblastoma (GBM) in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022....Improved median overall survival (OS) rates correlated with the absorbed tumor radiation dose....Specifically, patients receiving a therapeutic absorbed radiation dose (>100 Gray) had a median OS of 22.9 (95% CI of 8.8-42.3) months compared to those receiving a subtherapeutic absorbed radiation dose (<100 Gray) whose median OS was 5.6 months (95% CI of 1.6-9.4)....The Company plans to initiate the ReSPECT-GBM Phase 2 trial in the second half of 2022....The Company intends to begin the ReSPECT-GBM Phase 2 trial utilizing cGMP 186RNL drug, which will be available in the second half of 2022."
Commercial • P1 data • Trial status • Brain Cancer • CNS Tumor • Glioblastoma • Glioma • Oncology • Solid Tumor
|